Developing safety criteria for introducing new agents into neoadjuvant trials - Wikidata - awgldk - TriplyDB

Developing safety criteria for introducing new agents into neoadjuvant trials

Developing safety criteria for introducing new agents into neoadjuvant trials

http://www.wikidata.org/entity/Q33895825

about

Early phase clinical trials to identify optimal dosing and safety NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer Can we unlock the potential of IGF-1R inhibition in cancer therapy?Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Precision medicine and personalized breast cancer: combination pertuzumab therapy.Advances in the approach to novel drug clinical development for breast cancer.Phase 1 trial design: is 3 + 3 the best?Utility of neoadjuvant chemotherapy in the treatment of operable breast cancer.University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (afternoon panel discussion).

P2860

Q26865076-F62BFA0C-FDAB-4E36-9418-F007E8CC4DBD Q33655771-AC55CDA8-DDEC-4488-9766-2507CB109D93 Q34336988-14F2D32A-60B5-45CE-9AFF-B39E819F1822 Q36288987-A8AFB724-4F26-4B9C-850F-33C5325FAA53 Q37687975-16688DD1-7A99-4E64-A3CA-49FF934D1545 Q38206546-3C3C0ED3-3D50-4036-98C8-D79C1656F9FC Q38222466-479B9CC1-003D-4EE4-B520-E7865920A203 Q38328673-BBF2AF74-05D0-46CA-8CC4-B504790E48B4 Q47304892-FCD4E02D-2215-4992-ACA6-CA56B31501DC

P2860

Developing safety criteria for introducing new agents into neoadjuvant trials

http://www.wikidata.org/entity/Q33895825

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Developing safety criteria for introducing new agents into neoadjuvant trials

@ast

Developing safety criteria for introducing new agents into neoadjuvant trials

@en

type

label

Developing safety criteria for introducing new agents into neoadjuvant trials

@ast

Developing safety criteria for introducing new agents into neoadjuvant trials

@en

prefLabel

Developing safety criteria for introducing new agents into neoadjuvant trials

@ast

Developing safety criteria for introducing new agents into neoadjuvant trials

@en

P1433

Q33895825-3C6DFE8C-23B9-4D41-A358-07465ECC70E8

P1476

Q33895825-A8A8DCA2-6D21-4E12-B444-F5DA014F5BCE

P2093

Q33895825-18802B76-6412-4EC2-93BA-6E9D0CB4C8A3

Q33895825-18B72A52-D5D2-4DD1-B5E4-4D31B7D47A43

Q33895825-1FD42535-DF42-43F2-A398-BF9C01DB304C

Q33895825-22480146-3131-4E6F-B34B-9708F1778392

Q33895825-27DC51A6-C8BD-47B3-9EC8-AECDE7C538BA

Q33895825-2E61ED1F-DA40-489D-9787-38E8377C5678

Q33895825-33C2F295-C7C7-4F92-8503-2DA7276BAF8C

Q33895825-35DD36A6-E505-4378-89E1-CA3929B3F4DB

Q33895825-46526B53-B274-4386-B3B7-08048D16A7E4

Q33895825-479FCB55-FBA8-49A3-8E71-BCE5F44FEED5

P2860

Q33895825-1E8D9DE6-FCA1-4FBF-84C0-91C41FA69BE2

Q33895825-399A88FF-8FB0-4831-A62C-D9CBBEE4DA87

Q33895825-47546063-C4BD-4856-8029-372F7C959169

Q33895825-4846F427-09E1-4E48-8802-E2A855FAFA1D

Q33895825-4A7825F8-2DBF-43F5-A0A0-153C06203D2F

Q33895825-5A94E0D0-0975-40A2-93B4-4A20D464D61B

Q33895825-5B8B4D02-797F-416B-A459-6BB0A9F6FF70

Q33895825-67DAC240-922E-4F5C-8D2C-BD88D8ED660D

Q33895825-6AAF50E7-B137-416F-BE15-8ED3C5DD23DA

Q33895825-7FEC4C9B-9AB5-4084-BA67-FEC687D1EDF6

P304

Q33895825-6B521431-29D8-4A3E-B715-9D74CD2E8FE4

P31

Q33895825-BFA21737-4948-423C-97A7-E36EEBEB2370

P356

Q33895825-283841F1-4DE5-4BBC-8129-8F494E4AEB0B

P407

Q33895825-FEA2F12F-9477-41E8-A51E-837F9216669A

P433

Q33895825-9A903E95-6311-42BD-A6FF-87223B019259

P478

Q33895825-2BDCE7CF-EC3B-424D-B02B-EC81C8942A2F

P50

Q33895825-0CB11228-D666-4D77-8FC8-AA80103FED67

P577

Q33895825-013B24A7-0847-4966-AF3F-3C7F33022EE1

P698

Q33895825-063096F3-EEF1-44BC-B526-4B2681ADE371

P932

Q33895825-BEBA53CB-E937-4E8E-9020-5060CFBE0132

P356

1078-0432.CCR-12-2620

P1433

Clinical Cancer Research

P1476

Developing safety criteria for introducing new agents into neoadjuvant trials

@en

P2093

A Jo Chien

http://www.w3.org/2001/XMLSchema#string

Angela DeMichele

http://www.w3.org/2001/XMLSchema#string

Barbara A Parker

http://www.w3.org/2001/XMLSchema#string

Brian Leyland-Jones

http://www.w3.org/2001/XMLSchema#string

Chris Benz

http://www.w3.org/2001/XMLSchema#string

Debu Tripathy

http://www.w3.org/2001/XMLSchema#string

Donald A Berry

http://www.w3.org/2001/XMLSchema#string

Douglas Yee

http://www.w3.org/2001/XMLSchema#string

Gary Kelloff

http://www.w3.org/2001/XMLSchema#string

Hope Rugo

http://www.w3.org/2001/XMLSchema#string

P2860

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Economics of new oncology drug development.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Adaptive clinical trials in oncology.

Drug development and clinical trials--the path to an approved cancer drug.

P304

2817-2823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-2620

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Olufunmilayo Olopade

P577

2013-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23470967

http://www.w3.org/2001/XMLSchema#string

P932

4096560

http://www.w3.org/2001/XMLSchema#string